Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.13)
# 2,978
Out of 5,093 analysts
39
Total ratings
48.48%
Success rate
-5.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $66.78 | +40.76% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $43.19 | +124.59% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $18.52 | +115.98% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $20.17 | +222.26% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $891.79 | +2.04% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.69 | +728.40% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $222.75 | -0.34% | 5 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.16 | +131.48% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $12.51 | +83.85% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.49 | +141.45% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $22.13 | +668.19% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $4.42 | +352.49% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $234.97 | -12.33% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.26 | +574.85% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.54 | +294.48% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $91.14 | -34.17% | 1 | Oct 5, 2022 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $66.78
Upside: +40.76%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $43.19
Upside: +124.59%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $18.52
Upside: +115.98%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $20.17
Upside: +222.26%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $891.79
Upside: +2.04%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.69
Upside: +728.40%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $222.75
Upside: -0.34%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.16
Upside: +131.48%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $12.51
Upside: +83.85%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.49
Upside: +141.45%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $22.13
Upside: +668.19%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.42
Upside: +352.49%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $234.97
Upside: -12.33%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.26
Upside: +574.85%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.54
Upside: +294.48%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $91.14
Upside: -34.17%